Murthy SK, et al. - In order to better comprehend the real-world impact of biologic therapy in people with Crohn's illness (CD) and ulcerative colitis (UC), researchers assessed the impact of marketplace introduction of infliximab on the population rates of hospitalization and surgery and on the cost of the drug to the public payer. The introduction of infliximab in the marketplace did not yield anticipated decreases in population rates of IBD-related hospitalizations or intestinal resections despite robust market penetration among CD patients. The results of the study may be largely explained by misguided use of infliximab in CD patients and underuse of infliximab in UC patients.